

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Mark L. Boys, et al.

APPLICATION NO.: 10/583,782 : Examiner: Unknown

FILING DATE: October 4, 2004 : Group Art Unit: Unknown

TITLE: Substituted Pyrazinone Compounds For The  
Treatment of Inflammation

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT  
PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the references cited by the applicant(s), copies of which are enclosed.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a). It is believed the Examiner will concur with applicant's belief that the subject matter presently claimed is neither anticipated nor rendered obvious by the foregoing references.

It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

No fee should be required for this request. If, however, the Commissioner determines that any fee is due please charge it to Deposit Account No. 16-1445. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to deposit Account No. 16-1445. Two copies of this sheet are enclosed.

A prompt and favorable response is earnestly solicited.

Date: February 27, 2007

Respectfully submitted,

Robert T. Ronau

Robert T. Ronau

Attorney for Applicant(s)

Reg. No. 36,257

Pfizer Inc.  
Patent Department, MS 8260-1611  
Eastern Point Road  
Groton, Connecticut 06340  
(860) 441-5910